Hospital medicine (London, England : 1998)
2003-06-01
Leuprorelin: a leading role in advanced prostate cancer therapy.
Raj Persad
文献索引：Hosp. Med. 64(6) , 360-3, (2003)
全文：HTML全文
摘要
Leuprorelin is a luteinizing hormone-releasing hormone analogue, licensed in the UK for the treatment of advanced prostate cancer. This review highlights the efficacy and tolerance of this agent and the benefits provided for developing patient-centred therapy and optimizing patient quality of life.
相关化合物
| 结构式 | 名称/CAS号 | 分子式 | 全部文献 |
|---|---|---|---|
 |
亮丙瑞林
CAS:53714-56-0 |
C59H84N16O12 |
相关文献：
更多...
|
Estradiol, but not testosterone, heightens cortisol-mediated...
2014-05-01 [Am. J. Physiol. Regul. Integr. Comp. Physiol. 306(9) , R627-35, (2014)] |
|
Two different formulations with equivalent effect? Compariso...
2013-03-01 [Med. Oncol. 30(1) , 354, (2013)] |
|
Novasure as a mechanical endometrial preparation agent in la...
2012-01-01 [JSLS 16(4) , 537-41, (2012)] |
|
Comprehensive management of diffuse leiomyomatosis in a pati...
2013-12-01 [P. R. Health Sci. J. 32(4) , 200-2, (2013)] |
|
A rare case of lymphangiomyomatosis treated with leuprolide ...
2013-01-01 [Eur. J. Gynaecol. Oncol. 34(3) , 278-9, (2013)] |